Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax) identifier:
NCT03404960 (

Study Contact Information:

Principal Investigator: Kim Reiss Binder, MD  
Contact: Stacy Cowden by phone: 215-847-4589 or by email or Abramson Cancer Center Clinical Trials Service at 855-216-0098 or  by email.


About the Study

The purpose of this study is to look at the effectiveness, safety, and anti-cancer activity of the drug Niraparib (Zejula) combined with one of two immunotherapy agents: Ipilimumab (Yervoy) or Nivolumab (Opdivo) on patients with locally advanced or metastatic pancreatic cancer.  Patients in this study must also have previously received Platinum-based chemotherapy without evidence of disease progression.  NOTE: This study is no longer enrolling patients. 

Type of Study

This is a randomized, open label, two-arm study. Patients will be placed into one of the two study groups by chance.  All participating patients will know which combination of therapy drugs they will be receiving during the study. 

What the Study Entails

Group 1

Patients will receive Niraparib + Nivolumab.

Group 2 

Patients will receive Niraparib + Ipilimumab. 

Both Groups

For most of the study outcome measures, patients will be followed up to 42 months, although a few outcomes will be measured for up to 5 years.

Study Site

Philadelphia, PA
University of Pennsylvania, Abramson Cancer Center
Contact: Stacy Cowden by phone: 215-847-4589 or by email.      

Principal Investigator: Kim Reiss Binder, MD          

This Study is Open To:

Men and women age 18 years or older can participate if they meet the following criteria:

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.